GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NaviFUS Corp (ROCO:6872) » Definitions » Growth Rank

NaviFUS (ROCO:6872) Growth Rank : 0 (As of Jun. 20, 2024)


View and export this data going back to 2022. Start your Free Trial

What is NaviFUS Growth Rank?

NaviFUS has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


NaviFUS Growth Rank Related Terms

Thank you for viewing the detailed overview of NaviFUS's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


NaviFUS (ROCO:6872) Business Description

Traded in Other Exchanges
N/A
Address
No.246, Sec 3, Chengde Road, 12th Floor, Datong District, Taipei City, TWN, 103
NaviFUS Corp is a Biotech company providing novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery. Its product, the NaviFUS System, is designed to utilize non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision for better treatment outcomes. Its vision is to cater to CNS disease patients locally and globally by bringing therapeutic ultrasound technology to clinical use.

NaviFUS (ROCO:6872) Headlines

No Headlines